EGFR and KRAS in Colorectal Cancer

Advances in Clinical Chemistry

Volumn 51, Issue C, 2010, Pages 71-119

  Markman, Ben ^a   Javier Ramos, Francisco ^a   Capdevila, Jaume ^a   Tabernero, Josep ^a  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Biomarker; BRAF; Cetuximab; Colorectal cancer; Epidermal growth factor receptor; KRAS; Monoclonal antibody; Panitumumab; Predictive; Prognostic

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; RAS PROTEIN; TUMOR MARKER;

BLOOD; BOOK; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG ANTAGONISM; GENETICS; HUMAN; MUTATION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77955860591     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(10)51004-7     Document Type: Book

References (112)

1. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21:2787-2799.
2. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7:505-516.
3. Harris R.C., Chung E., Coffey R.J. EGF receptor ligands. Exp. Cell Res. 2003, 284:2-13.
4. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 1998, 74:49-139.
5. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
6. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997, 410:83-86.
7. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
8. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
9. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593-1611.
10. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 2001, 7:1850-1855.
11. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995, 55:3140-3148.
12. Chu C.T., Everiss K.D., Wikstrand C.J., Batra S.K., Kung H.J., Bigner D.D. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 1997, 324:855-861.
13. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1:1311-1318.
14. Sato J.D., Kawamoto T., Le A.D., Mendelsohn J., Polikoff J., Sato G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1983, 1:511-529.
15. Herbst R.S., Kim E.S., Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin. Biol. Ther. 2001, 1:719-732.
16. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 2000, 6:2166-2174.
17. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G., Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999, 59:1236-1243.
18. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001, 38:17-23.
19. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
20. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357:2040-2048.
21. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:2311-2319.
22. Tabernero J., Van Cutsem E., Diaz-Rubio E., Cervantes A., Humblet Y., Andre T., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2007, 25:5225-5232.
23. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:663-671.
24. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., ChangChien C.R., Makhson A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
25. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007, 25:1658-1664.
26. Saltz L., Kies M., Abbruzzese J., Azarnia N., Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. 2003, 22. (abstr 817).
27. Peeters M., Siena S., Van Cutsem E., Sobrero A., Hendlisz A., Cascinu S., et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009, 115:1544-1554.
28. Tejpar S., Peeters M., Humblet Y., Gelderblom H., Vermorken J., Viret F., et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J. Clin. Oncol. (Meeting Abstracts) 2007, 25:4037.
29. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22:1201-1208.
30. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23:1803-1810.
31. Shia J., Klimstra D.S., Li A.R., Qin J., Saltz L., Teruya-Feldstein J., et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod. Pathol. 2005, 18:1350-1356.
32. Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 2006, 24:4914-4921.
33. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6:279-286.
34. Sartore-Bianchi A., Moroni M., Veronese S., Carnaghi C., Bajetta E., Luppi G., et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 2007, 25:3238-3245.
35. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
36. Tsuchihashi Z., Khambata-Ford S., Hanna N., Janne P.A. Responsiveness to cetuximab without mutations in EGFR. N. Engl. J. Med. 2005, 353:208-209.
37. Barber T.D., Vogelstein B., Kinzler K.W., Velculescu V.E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 2004, 351:2883.
38. Rajalingam K., Schreck R., Rapp U.R., Albert S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 2007, 1773:1177-1195.
39. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim. Biophys. Acta 2005, 1756:81-82.
40. Barbacid M. ras genes. Annu. Rev. Biochem. 1987, 56:779-827.
41. Bos J.L., Fearon E.R., Hamilton S.R., Verlaan-de Vries M., van Boom J.H., van der Eb A.J., et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327:293-297.
42. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988, 319:525-532.
43. Loupakis F., Pollina L., Stasi I., Ruzzo A., Scartozzi M., Santini D., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:2622-2629.
44. Bazan V., Migliavacca M., Zanna I., Tubiolo C., Grassi N., Latteri M.A., et al. Specific codon 13K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12K-ras mutations are associated with mucinous histotype. Ann. Oncol. 2002, 13:1438-1446.
45. Dix B.R., Robbins P., Soong R., Jenner D., House A.K., Iacopetta B.J. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int. J. Cancer 1994, 59:747-751.
46. Tortola S., Marcuello E., Gonzalez I., Reyes G., Arribas R., Aiza G., et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J. Clin. Oncol. 1999, 17:1375-1381.
47. Benhattar J., Losi L., Chaubert P., Givel J.C., Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993, 104:1044-1048.
48. Andreyev H.J., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J. Natl. Cancer Inst. 1998, 90:675-684.
49. Andreyev H.J., Norman A.R., Cunningham D., Oates J., Dix B.R., Iacopetta B.J., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 2001, 85:692-696.
50. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
51. Ogino S., Meyerhardt J.A., Irahara N., Niedzwiecki D., Hollis D., Saltz L.B., et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 2009, 15:7322-7329.
52. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
53. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
54. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
55. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 2007, 96:1166-1169.
56. De Roock W., Piessevaux H., De Schutter J., Janssens M., De Hertogh G., Personeni N., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008, 19:508-515.
57. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25:3230-3237.
58. Cappuzzo F., Varella-Garcia M., Finocchiaro G., Skokan M., Gajapathy S., Carnaghi C., et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br. J. Cancer 2008, 99:83-89.
59. Tejpar S., Peeters M., Humblet Y., Gelderblom H., Vermorken J., De Hertogh G., et al. The EVEREST study: relationship between efficacy and K-ras mutation status in patients with irinotecan-refractory mCRC treated with irinotecan and standard or escalating doses of cetuximab. Ann. Oncol. 2008, 19:vi14.
60. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
61. Tabernero J., Cervantes A., Ciardiello F., Vega-Villegas E., Macarulla T., Rodriguez-Braun E., et al. Correlation of efficacy to KRAS status (wt vs. mut) in patients (pts) with metastatic colorectal cancer (mCRC), treated with weekly (q1w) and q2w schedules of cetuximab combined with FOLFIRI 2008, Abstract 435.
62. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:563-572.
63. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:672-680.
64. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE) 2008, Abstract 273.
65. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27:2091-2096.
66. Lochan R., White S.A., Manas D.M. Liver resection for colorectal liver metastasis. Surg. Oncol. 2007, 16:33-45.
67. Folprecht G., Gruenberger T., Bechstein W.O., Raab H.R., Lordick F., Hartmann J.T., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010, 11:38-47.
68. Bertolini F., Chiara S., Bengala C., Antognoni P., Dealis C., Zironi S., et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73:466-472.
69. Machiels J.P., Sempoux C., Scalliet P., Coche J.C., Humblet Y., Van Cutsem E., et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann. Oncol. 2007, 18:738-744.
70. Bengala C., Bettelli S., Bertolini F., Salvi S., Chiara S., Sonaglio C., et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann. Oncol. 2009, 20:469-474.
71. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 2002, 161:1961-1971.
72. Atkins D., Reiffen K.A., Tegtmeier C.L., Winther H., Bonato M.S., Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem. 2004, 52:893-901.
73. Juan T., Suggs S., Wolf M., Sarosi I., Freeman D., Oliner K., et al. A comparability study of 4 commercial KRAS tests 2008, Abstract 1811.
74. Tol J., Dijkstra J.R., Vink-Borger M.E., Nagtegaal I.D., Punt C.J., van Krieken J.H., et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J. Cell. Mol. Med. 2009, (Epub ahead of print).
75. Jung A., Baretton G., Dietel M., Gabbert H., Kreipe H., Schlake W., et al. The German quality assurance system for the molecular-pathological detection of KRAS-mutations in colorectal cancer. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:4018.
76. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
77. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
78. Fransen K., Klintenas M., Osterstrom A., Dimberg J., Monstein H.J., Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25:527-533.
79. Calistri D., Rengucci C., Seymour I., Lattuneddu A., Polifemo A.M., Monti F., et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J. Cell. Physiol. 2005, 204:484-488.
80. Mercer K.E., Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 2003, 1653:25-40.
81. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:5705-5712.
82. Tie J., Sieber O.M., Gibbs P., Lipton L., Jorissen R.N., Langland R., et al. Selecting subjects for a therapeutic target in colorectal cancer (CRC): using a clinical database to enrich for patients harboring the BRAFV600E mutation. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:11003.
83. Lambrechts D., De Roock W., Prenen H., De Schutter J., Jacobs B., Biesmans B., et al. The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:4020.
84. Kohne C., Stroiakovski D., Chang-chien C., Lim R., Pinter T., Bodoky G., et al. Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:4068.
85. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
86. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
87. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
88. Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 2007, 97:1139-1145.
89. Perrone F., Lampis A., Orsenigo M., Di Bartolomeo M., Gevorgyan A., Losa M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 2009, 20:84-90.
90. Loupakis F., Pollina L., Stasi I., Ruzzo A., Scartozzi M., Santini D., et al. PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. J. Clin. Oncol. 2009, 27:2622-2629.
91. Mounawar M., Mukeria A., Le Calvez F., Hung R.J., Renard H., Cortot A., et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res. 2007, 67:5667-5672.
92. Oden-Gangloff A., Di Fiore F., Bibeau F., Lamy A., Bougeard G., Charbonnier F., et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br. J. Cancer 2009, 100:1330-1335.
93. Jonker D.J., Karapetis C., Harbison C., O'Callaghan C.J., Tu D., Simes R.J., et al. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC). J. Clin. Oncol. (Meeting Abstracts) 2009, 27:4016.
94. Prenen H., Jacobs B., De Roock W., Van Oirbeek R., Biesmans B., De Schutter J., et al. Use of amphiregulin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:4019.
95. Garm Spindler K.L., Pallisgaard N., Rasmussen A.A., Lindebjerg J., Andersen R.F., Cruger D., et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann. Oncol. 2009, 20:879-884.
96. Bibeau F., Lopez-Crapez E., Di Fiore F., Thezenas S., Ychou M., Blanchard F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 2009, 27:1122-1129.
97. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002, 62:200-207.
98. Scartozzi M., Bearzi I., Mandolesi A., Loupakis F., Zaniboni A., Berardi R., et al. Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:4017.
99. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009, 20:1223-1229.
100. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14:985-990.
101. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 2007, 6:541-555.
102. Flaherty K., Puzanov I., Sosman J., Kim K., Ribas A., McArthur G., et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:9000.
103. Sebolt-Leopold J.S. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin. Cancer Res. 2008, 14:3651-3656.
104. Lorusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 2005, 23:5281-5293.
105. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004, 22:4456-4462.
106. Lorusso P., Krishnamurthi S., Rinehart J.R., Nabell L., Croghan G., Varterasian M., et al. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J. Clin. Oncol. (Meeting Abstracts) 2005, 23:3011.
107. Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 2008, 26:2139-2146.
108. LoRusso P., Markman B., Tabernero J., Shazer R., Nguyen L., Heath E., et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:3502.
109. Shapiro G., Kwak E., Baselga J., Rodon J., Scheffold C., Laird A.D., et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:3500.
110. Wagner A.J., Von Hoff D.H., LoRusso P.M., Tibes R., Mazina K.E., Ware J.A., et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts) 2009, 27:3501.
111. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
112. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118:2609-2619.